Unlabeled Use:
Contraindicated in:
Use Cautiously in:
CV: hypotension, bradycardia, QT interval prolongation, TORSADES DE POINTES.
Derm: flushing, sweating.
EENT: blurred vision, diplopia, miosis.
Endo: adrenal insufficiency.
GI: constipation, nausea, vomiting.
GU: urinary retention.
Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams.
Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA).
Misc: allodynia, opioid-induced hyperalgesia, physical dependence, psychological dependence, tolerance.
Drug-Drug:
Drug-Natural Products:
Moderate to Severe Pain
Opioid Detoxification
Dolophine, Methadose
Absorption: 50% absorbed following oral administration. IV administration results in complete bioavailability.
Distribution: Widely distributed to tissues.
Protein Binding: 8590%.
Metabolism/Excretion: Mostly metabolized by the liver; some metabolites are active and may accumulate with chronic administration. Primarily excreted in the urine (<10% as unchanged drug).
Half-life: 1525 hr (↑ with chronic use).
(analgesic effect)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 3060 min | 90120 min | 412 hr |
IM, IV, SUBQ | 1020 min | 60120 min | 812 hr |
NDC Code*